摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

rac-2,4-dibromo-N-(2,2,2-trifluoroethyl)-butanamide | 178946-14-0

中文名称
——
中文别名
——
英文名称
rac-2,4-dibromo-N-(2,2,2-trifluoroethyl)-butanamide
英文别名
2,4-dibromo-N-(2,2,2-trifluoroethyl)butanamide
rac-2,4-dibromo-N-(2,2,2-trifluoroethyl)-butanamide化学式
CAS
178946-14-0
化学式
C6H8Br2F3NO
mdl
——
分子量
326.939
InChiKey
KLBNVJILLBGDRV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    rac-2,4-dibromo-N-(2,2,2-trifluoroethyl)-butanamidesodium hydroxide 、 Dowex 2x 10 、 三苯基膦 作用下, 以 二氯甲烷 为溶剂, 生成 (2R,6R,7R)-7-tert-Butoxycarbonylamino-8-oxo-3-[2-oxo-1-(2,2,2-trifluoro-ethyl)-pyrrolidin-(3E)-ylidenemethyl]-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2-carboxylic acid benzhydryl ester
    参考文献:
    名称:
    Synthesis and Structure−Activity Relationship of (Lactamylvinyl)cephalosporins Exhibiting Activity against Staphylococci, Pneumococci, and Enterococci
    摘要:
    The synthesis and structure-activity relationships of a new class of vinylcephalosporins substituted with a lactamyl residue (1) are described. These compounds show excellent activity against enterococci and retain the broad spectrum activity of third-generation cephalosporins such as ceftriaxone.
    DOI:
    10.1021/jm950886v
  • 作为产物:
    参考文献:
    名称:
    Synthesis and Structure−Activity Relationship of (Lactamylvinyl)cephalosporins Exhibiting Activity against Staphylococci, Pneumococci, and Enterococci
    摘要:
    The synthesis and structure-activity relationships of a new class of vinylcephalosporins substituted with a lactamyl residue (1) are described. These compounds show excellent activity against enterococci and retain the broad spectrum activity of third-generation cephalosporins such as ceftriaxone.
    DOI:
    10.1021/jm950886v
点击查看最新优质反应信息

文献信息

  • Cephalosporin antibiotics
    申请人:Hoffmann-La Roche Inc.
    公开号:US05523400A1
    公开(公告)日:1996-06-04
    The present invention relates to compounds of the formula ##STR1## wherein R.sup.1 is an acyl group derived from a carboxylic acid, hydrogen, or an amino protecting group; R.sup.2 is hydrogen, hydroxy, lower alkyl-Q.sub.p -, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl-Q.sub.p -, aryl-Q.sub.p -, aryloxy, aralkoxy or a heterocyclic ring, the lower alkyl, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl, aryl, aryloxy, aralkoxy and the heterocyclic ring being unsubstituted or substituted with at least one group selected from carboxy, amino, nitro, oxo, cycloalkyl, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, --CONR.sup.4 R.sup.5, --N(R.sup.5)COOR.sup.9, R.sup.5 CO--, R.sup.5 OCO-- or R.sup.5 COO-- where R.sup.4 is hydrogen, lower alkyl, or cycloalkyl; R.sup.5 is hydrogen or lower alkyl; R.sup.9 is lower alkyl, lower alkenyl or a carboxylic acid protecting group; Q is --CO-- or --SO.sub.2 --; m is 0 or 1; n is 0, 1 or 2; p is 0 or 1; as well as readily hydrolyzable esters thereof, pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I and of their esters and salts. The compounds are useful as oral or parenteral antibiotics against a broad spectrum of organisms.
    本发明涉及以下式的化合物:其中 R.sup.1 是从羧酸、氢或氨基保护基衍生的酰基;R.sup.2 是氢、羟基、较低烷基-Q.sub.p-、环烷基、较低烷氧基、较低烯基、环烯基、较低炔基、芳基烷基-Q.sub.p-、芳基-Q.sub.p-、芳氧基、芳基烷氧基或杂环环,其中较低烷基、环烷基、较低烷氧基、较低烯基、环烯基、较低炔基、芳基烷基、芳基、芳氧基、芳基烷氧基和杂环环未取代或取代至少一个羧基、氨基、硝基、氧代、环烷基、氰基、较低烷基、较低烷氧基、羟基、卤素、--CONR.sup.4R.sup.5、--N(R.sup.5)COOR.sup.9、R.sup.5CO--、R.sup.5OCO--或R.sup.5COO--中选择的至少一个基团;其中 R.sup.4 是氢、较低烷基或环烷基;R.sup.5 是氢或较低烷基;R.sup.9 是较低烷基、较低烯基或羧酸保护基;Q 是--CO--或--SO.sub.2--;m 为 0 或 1;n 为 0、1 或 2;p 为 0 或 1;以及这些化合物的易水解酯、药用上可接受的盐以及公式 I 中的化合物及其酯和盐的水合物。这些化合物可用作口服或静脉注射抗生素,对广谱生物有作用。
  • Cephalosporin derivatives
    申请人:F. HOFFMANN-LA ROCHE AG
    公开号:EP0620225A1
    公开(公告)日:1994-10-19
    Cephalosporin derivatives of the general formula wherein R¹is an acyl group derived from a carboxylic acid; R²is hydrogen, hydroxy, lower alkyl-Qm, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl-Qm, aryl-Qm, aryloxy, aralkoxy or a heterocyclic ring, the lower alkyl, cycloalkyl, lower alkoxy, lower alkenyl, cycloalkenyl, lower alkynyl, aralkyl, aryl, aryloxy, aralkoxy and the heterocyclic ring being unsubstituted or substituted with at least one group selected from carboxy, amino, nitro, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, -CONR⁴R⁵, -N(R⁵)COOR⁹, R⁵CO-, R⁵OCO- or R⁵COO- where R⁴ is hydrogen, lower alkyl, or cycloalkyl; R⁵ is hydrogen or lower alkyl; R⁹ is hydrogen, lower alkyl, lower alkenyl or a carboxylic acid protecting group; Qis -CO- or -SO₂-; mis 0 or 1; nis 0, 1 or 2; as well as readily hydrolyzable esters thereof, pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I and of their esters and salts. The products are antibacterially active.
    通式如下的头孢菌素衍生物 其中 R¹ 是源自羧酸的酰基; 杂环未被取代或被至少一个选自羧基、氨基、硝基、氰基、低级烷基、低级烷氧基、羟基、卤代烷基、卤代烯基、环烯基、低级炔基、芳烷基、芳氧基、芳烷氧基低级烷氧基、羟基、卤素、-CONR⁴R⁵、-N(R⁵)COOR⁹、R⁵CO-、R⁵OCO- 或 R⁵COO- 其中 R⁴ 是氢、低级烷基或环烷基;R⁵ 是氢或低级烷基; R⁹ 是氢、低级烷基、低级烯基或羧酸保护基团; Q 是-CO-或-SO₂-; mis 0 或 1; n为 0、1 或 2; 以及其易于水解的酯、所述化合物的药学上可接受的盐和式 I 化合物及其酯和盐的水合物。 这些产品具有抗菌活性。
  • US5523400A
    申请人:——
    公开号:US5523400A
    公开(公告)日:1996-06-04
  • Synthesis and Structure−Activity Relationship of (Lactamylvinyl)cephalosporins Exhibiting Activity against Staphylococci, Pneumococci, and Enterococci
    作者:Ingrid Heinze-Krauss、Peter Angehrn、Philippe Guerry、Paul Hebeisen、Christian Hubschwerlen、Ivan Kompis、Malcolm G. P. Page、Hans G. F. Richter、Valérie Runtz、Henri Stalder、Urs Weiss、Chung-Chen Wei
    DOI:10.1021/jm950886v
    日期:1996.1.1
    The synthesis and structure-activity relationships of a new class of vinylcephalosporins substituted with a lactamyl residue (1) are described. These compounds show excellent activity against enterococci and retain the broad spectrum activity of third-generation cephalosporins such as ceftriaxone.
查看更多